NIH Trial Demonstrates That Even Modest Weight Loss Improves Cardiovascular Disease Risk Factors Among Overweight/Obese People w
28 Juni 2007 - 12:00PM
PR Newswire (US)
Study Shows That Use of Meal Replacements, Like Slim-Fast, Plays a
Major Role ENGLEWOOD CLIFFS, N.J., June 28 /PRNewswire/ -- The
1-year results of a clinical study funded by the National
Institutes of Health confirm that following a calorie-controlled
diet which includes meal replacements play a significant role in
promoting modest weight loss that translates into substantial
health-related benefits for overweight or obese people with type 2
diabetes, including significant improvements in risk factors for
heart disease. The Look AHEAD (Action for Health in Diabetes) study
is the first large clinical trial designed to demonstrate the
effect of weight loss on cardiovascular risk, morbidity and
mortality in overweight individuals with type 2 diabetes. The
16-center trial which enrolled 5,145 overweight people with type 2
diabetes will examine cardiovascular morbidity and mortality for up
to 12 years in persons randomly assigned to one of two conditions:
Diabetes Support and Education (DSE) who receive usual medical
care, and Intensive Lifestyle Intervention (ILI) who had a goal to
lost 7% or more of initial weight by following a reduced-calorie
diet in which people replaced two meals and one snack a day with
liquid meal replacement shakes and meal bars for the first 6
months, and continued to replace one meal a day for the next 6
months, along with an increase in physical activity to 175 minutes
or more/week (about 35 minutes of moderate exercise 5 days/week).
After one year, those people in the ILI group lost an average of
8.6% of their body weight, versus only 0.7% among people in the DSE
group. This difference in weight loss resulted in more significant
improvements in diabetes control and cardiovascular risk factors,
including a substantial reduction in hemoglobin A1c to 6.6% and
greater reductions in blood pressure and triglyceride levels, as
well as a reduced need for blood pressure, lipid-lowering and
diabetes medications in the ILI versus the DSE group. Participants
in the ILI group also showed a 21% improvement in cardiovascular
fitness as compared with 5.8% among DSE participants "The data
affirm what we've always thought: that losing weight if you have
type 2 diabetes translates into a variety of benefits. Weight loss
is the first and initially most important strategy to try. So, if
you can lose weight, you'll need less medication, have better
control of diabetes, and lower blood pressure and lipid levels. An
important strategy to accomplishing that weight loss is to consider
adding meal replacements to your program on a regular and
consistent basis, and to think of that as a lifestyle change that
you're going to make and stick with for the foreseeable future"
said John Foreyt, PhD. Professor of Medicine at Baylor College of
Medicine and Principal Investigator of the Houston, Texas Baylor
site of the Look AHEAD study. "The one-year results of the Look
AHEAD Study demonstrate the significant health-related benefits
that can be realized from a modest and achievable weight loss of 5%
to 10% of body weight (about 15 pounds), and the important role
that meal replacements play in making it easier for people to
reduce their calorie intake by providing portion control along with
good nutrition," said Patricia Groziak, M.S., R.D., Unilever Senior
Manager, Medical Marketing for Slim-Fast. "This is encouraging news
not only for the nearly 21 million people with diabetes in the U.S.
but also for the millions of overweight and obese Americans who are
at risk for developing diabetes and who continue to struggle with
losing weight. Slim-Fast offers a convenient, simple and satisfying
way to lose weight, and we are committed to continuously finding
solutions for dieters to help them achieve their goals, a
commitment that is supported by the results of over 35 published
clinical studies. More Information about the Look AHEAD Study The
Look AHEAD study included 5,145 overweight or obese people with
type 2 diabetes who were randomly assigned to either Intensive
Lifestyle Intervention (ILI) or usual care in the Diabetes Support
and Education (DSE) group. Participants were ages 45 to 74 and all
had type 2 diabetes and a body mass index (BMI) greater than 25
kg/m2 (>27 kg/m2 if taking insulin). A BMI between 18.5 and
24.9kg/m2 is considered a healthy body weight. The Look AHEAD study
began in 2001 and is scheduled to conclude in 2012. Results at one
year showed the following: -- 72.7% in the ILI group achieved the
American Diabetes Association's (ADA) goal for diabetes control
(defined as a Hemoglobin A1c
Unilever NV (NYSE:UN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Unilever NV (NYSE:UN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
Echtzeit-Nachrichten über Unilever NV (New York Börse): 0 Nachrichtenartikel
Weitere Unilever N V N Y News-Artikel